Polycystic ovarian syndrome
Conditions
Interventions
metformin+Chinese medicine placebo:metformin+Chinese medicine placebo
metformin+Chinese medicine sequential treatment:metformin+Chinese medicine sequential treatment
Sponsors
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
Female
Age
20 Years to 35 Years
Inclusion criteria
Inclusion criteria: 1) Meet the diagnostic criteria of Rotterdam PCOS: 1) dilute ovulation or anovulation; Hyperandrogenemia and/or clinical manifestations of hyperandrogenism, such as hypertrichosis, acne, acanthosis nigricans, etc.; (3) polycystic ovarian changes: at least one ovarian follicle with a diameter of 2~9mm =12, and (or) ovarian volume > 10mL. PCOS can be diagnosed if two of these conditions are met and other diseases that may cause hyperandrogen are excluded. 2) In line with traditional Chinese medicine spleen kidney Yang deficiency phlegm-dampness diagnostic criteria: waist and knees weak, fatigue and cold, thin loose stool, dizziness chest tightness, limb fatigue, lethargy; The amount under the band is too much; Pale and fat tongue, white and greasy fur, deep and smooth pulse; 3) Normal sexual life after marriage for more than 1 year without pregnancy, existing pregnancy intention; 4) Han women aged between 20 and 35; 5) The patient agrees to accept the treatment method of the group and signs the informed consent.
Exclusion criteria
Exclusion criteria: Patients with any of the following conditions were excluded. 1) Oral contraceptives, glucocorticoids, anti-estrogen drugs, ovulation stimulating agents, diabetes drugs or other steroid drugs within 3 months; 2) Patients who are pregnant or breastfeeding; 3) Patients with serious primary diseases of the heart, liver, lung, kidney, brain or blood system, or with mental illness; 4) Endocrine disorders caused by other primary diseases, such as adrenal hyperplasia, hyperprolactinemia, thyroid diseases or tumors; 5) Serious adverse reactions to the drugs in this study; 6) Patients who are participating in clinical trials of other drugs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| clinical pregnancy rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| live birth rate;HDL;menstrual cycle;Zung-SAS/Zung-SDS;insulin release test;Triglycerides;TCM symptom score;glucose tolerance test;SF-36;ongoing pregnancy rate;Total cholesterol;LDL; | — |
Countries
China
Contacts
Public ContactZhang mingmin
Tongji hospital, Tongji medical college, Huazhong university of science and technology
Outcome results
None listed